Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Esteban Martinez

Showing results (91-100 of 168) with videos related to

Pageof 17
Sort By:
AIDS Research and Human Retroviruses|April 9, 2008
Prevalence and clinical relevance of occult hepatitis B in the fibrosis progression and antiviral response to INF therapy in HIV-HCV-coinfected patientsMontserrat Laguno, Maria Larrousse, José Luis Blanco, et al.
HIV Medicine|May 20, 2025
Knowledge about biomedical HIV prevention among healthcare workers: A cross-sectional study in Europe and Central AsiaAna Mendez-Lopez, Fiona Burns, Ann Sullivan, et al.
The Journal of Antimicrobial Chemotherapy|May 5, 2022
Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia: a pilot studyJosé L Blanco, Jhon Rojas, Elisa de Lazzari, et al.
Antiviral Therapy|January 18, 2005
Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis CMontserrat Laguno, Jordi Blanch, Javier Murillas, et al.
The Journal of Antimicrobial Chemotherapy|August 2, 2020
Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular diseaseAna Gonzalez-Cordon, Lambert Assoumou, Miguel Camafort, et al.
The Journal of Antimicrobial Chemotherapy|July 22, 2021
Factors associated with the use and composition of two-drug regimens in a large single-centre HIV cohortElisa de Lazzari, Ana Gonzalez-Cordon, Alexy Inciarte, et al.
The Journal of Antimicrobial Chemotherapy|June 25, 2025
48 Week body composition changes in persons with HIV switching to dolutegravir plus lamivudine: a planned subanalysis of the DOLAM randomized clinical trialElisa de Lazzari, Silvana Di Gregorio, Jhon Rojas, et al.
AIDS (London, England)|December 6, 2024
Epidemiological, clinical and mortality trends in people with HIV over 60 years in the PISCIS population-based cohort from Catalonia and Balearic IslandsAndreu Bruguera, Daniel K Nomah, Sergio Moreno-Fornés, et al.
Antiviral Therapy|June 27, 2007
The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patientsAna Milinkovic, Esteban Martinez, Sonia López, et al.
Circulation|June 21, 2008
Prevention strategies for cardiovascular disease in HIV-infected patientsJames H Stein, Colleen M Hadigan, Todd T Brown, et al.
Pageof 17

Showing results (91-100 of 168) with videos related to

Sort By:
Pageof 17
AIDS Research and Human Retroviruses|April 9, 2008
Prevalence and clinical relevance of occult hepatitis B in the fibrosis progression and antiviral response to INF therapy in HIV-HCV-coinfected patientsMontserrat Laguno, Maria Larrousse, José Luis Blanco, et al.
HIV Medicine|May 20, 2025
Knowledge about biomedical HIV prevention among healthcare workers: A cross-sectional study in Europe and Central AsiaAna Mendez-Lopez, Fiona Burns, Ann Sullivan, et al.
The Journal of Antimicrobial Chemotherapy|May 5, 2022
Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia: a pilot studyJosé L Blanco, Jhon Rojas, Elisa de Lazzari, et al.
Antiviral Therapy|January 18, 2005
Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis CMontserrat Laguno, Jordi Blanch, Javier Murillas, et al.
The Journal of Antimicrobial Chemotherapy|August 2, 2020
Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular diseaseAna Gonzalez-Cordon, Lambert Assoumou, Miguel Camafort, et al.
The Journal of Antimicrobial Chemotherapy|July 22, 2021
Factors associated with the use and composition of two-drug regimens in a large single-centre HIV cohortElisa de Lazzari, Ana Gonzalez-Cordon, Alexy Inciarte, et al.
The Journal of Antimicrobial Chemotherapy|June 25, 2025
48 Week body composition changes in persons with HIV switching to dolutegravir plus lamivudine: a planned subanalysis of the DOLAM randomized clinical trialElisa de Lazzari, Silvana Di Gregorio, Jhon Rojas, et al.
AIDS (London, England)|December 6, 2024
Epidemiological, clinical and mortality trends in people with HIV over 60 years in the PISCIS population-based cohort from Catalonia and Balearic IslandsAndreu Bruguera, Daniel K Nomah, Sergio Moreno-Fornés, et al.
Antiviral Therapy|June 27, 2007
The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patientsAna Milinkovic, Esteban Martinez, Sonia López, et al.
Circulation|June 21, 2008
Prevention strategies for cardiovascular disease in HIV-infected patientsJames H Stein, Colleen M Hadigan, Todd T Brown, et al.
Pageof 17